Meridian Bioscience Launches a Complete Solution to Support Liquid Biopsy Cancer Diagnostics
October 07 2020 - 9:00AM
Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading provider of
diagnostic testing solutions and life science raw materials,
announced today that it has launched a complete solution improving
the development of cancer diagnostic tests, allowing direct RNA and
DNA detection from liquid biopsy samples such as whole blood.
In cancer diagnosis, liquid biopsy has emerged
as a fast and sensitive alternative to conventional tissue biopsy,
providing a non-invasive approach for the detection and monitoring
of circulating cancer biomarkers such as circulating tumour cells
(CTC), circulating tumor DNA (ctDNA) or non-coding RNA (ncRNA) in
the blood stream. The establishment of molecular assays to detect
these biomarkers is usually challenging, especially at low
concentrations, due to the sample variability and inhibitory
properties of the specimen.
Meridian Bioscience has developed tools to
overcome these challenges with two novel inhibitor-resistant qPCR
chemistries for the detection of DNA and RNA molecules directly
from liquid biopsy samples without the need for nucleic acid
extraction. These qPCR mixes are ideal tools for developing
sensitive assays and workflows that require fast turnaround times
(TAT) and minimal sample processing while ensuring high specificity
of the detection.
“The ability of these qPCR mixes to tolerate
high level of inhibitors present in blood allows the development of
simpler and faster assays, where the limit of detection (LOD) can
be improved further by introducing more sample in the reaction,”
said Florent Chang-Pi-Hin, Ph.D., Senior Director, Research &
Development. “We have seen a dramatic increase in interest in our
products used for cancer biomarker detection, not only proving the
interest of cancer diagnostic companies in such qPCR mixes but it
also highlights the quality of our chemistries. It is important
that we continue developing additional tools like these that
facilitate cancer prognosis, diagnosis, and therapy.”
Todd Howren, Ph.D., Vice President, Global Sales
Life Science, added, “studies have confirmed that our qPCR mixes
for liquid biopsy applications exhibit a superior sensitivity
compared to other mixes, with earlier Ct values even in difficult
conditions such as 20% blood.”
Meridian is committed to suppling innovative
solutions to the diagnostic industry to simplify and accelerate
development of superior diagnostic assays. For more information on
partnering with Meridian Bioscience, please visit
meridianlifescience.com or email
todd.howren@meridianlifescience.com.
About Meridian Bioscience,
Inc.Meridian is a fully integrated life science company
that develops, manufactures, markets and distributes a broad range
of innovative diagnostic products. We are dedicated to developing
and delivering better solutions that give answers with speed,
accuracy and simplicity that are redefining the possibilities of
life from discovery to diagnosis. Through discovery and
development, we provide critical life science raw materials used in
immunological and molecular tests for human, animal, plant, and
environmental applications. Through diagnosis, we provide
diagnostic solutions in areas including gastrointestinal and upper
respiratory infections and blood lead level testing. We build
relationships and provide solutions to hospitals, reference
laboratories, research centers, veterinary testing centers,
physician offices, diagnostics manufacturers, and biotech companies
in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ
Global Select Market, symbol VIVO. Meridian’s website address is
www.meridianbioscience.com.
Contact:Charlie WoodVice President – Investor
RelationsMeridian Bioscience, Inc.Phone: +1 513.271.3700Email:
mbi@meridianbioscience.com
Meridian Bioscience (NASDAQ:VIVO)
Historical Stock Chart
From Oct 2024 to Nov 2024
Meridian Bioscience (NASDAQ:VIVO)
Historical Stock Chart
From Nov 2023 to Nov 2024